Global Registry and Natural History Study for Mitochondrial Disorders
Launched by LMU KLINIKUM · Sep 23, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Global Registry and Natural History Study for Mitochondrial Disorders is a research project aimed at understanding various mitochondrial diseases, which are conditions that affect how our cells produce energy. The study will create a worldwide database to gather information from patients with these disorders, making it easier for researchers to learn more about their effects, measure health outcomes, and develop new treatments. This is a chance for patients from all walks of life to contribute to important research that can help improve understanding and care for these complex conditions.
To be eligible for this study, participants should either have a suspected or confirmed mitochondrial disease and be willing to take part in the research. Since the study is open to all ages and genders, many individuals and families may qualify. Participants can expect to share their experiences and health information, which will help researchers gain valuable insights into these diseases. This study is currently recruiting, so it’s a good opportunity for those interested in contributing to the advancement of knowledge in mitochondrial disorders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • suspected or confirmed mitochondrial disease
- • willingness to participate
- Exclusion Criteria:
- • unwillingness to participate
About Lmu Klinikum
LMU Klinikum is a leading academic medical center affiliated with Ludwig Maximilian University in Munich, Germany. Renowned for its commitment to innovative research and high-quality patient care, LMU Klinikum plays a pivotal role in advancing medical science through clinical trials and translational research. With a multidisciplinary approach, the institution collaborates with various stakeholders, including healthcare professionals, researchers, and industry partners, to facilitate groundbreaking studies that aim to improve therapeutic outcomes and enhance understanding of complex diseases. Its state-of-the-art facilities and expert clinical teams ensure the highest standards of safety and efficacy in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Münster, , Germany
Innsbruck, , Austria
Salzburg, , Austria
Berlin, , Germany
Bonn, , Germany
Düsseldorf, , Germany
Frankfurt Am Main, , Germany
Freiburg, , Germany
Halle/Saale, , Germany
Hamburg, , Germany
Hamburg, , Germany
Hamburg, , Germany
Heidelberg, , Germany
Köln, , Germany
München, , Germany
Reutlingen, , Germany
Tübingen, , Germany
Ulm, , Germany
Pisa, , Italy
Munich, Bavaria, Germany
Patients applied
Trial Officials
Thomas Klopstock, Prof. Dr.
Principal Investigator
LMU Klinikum, Munich
Michelangelo Mancuso, Prof. Dr.
Principal Investigator
Università di Pisa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials